Usage of vildagliptin among patients with type 2 diabetes mellitus attending a public primary healthcare clinics in Kuala Selangor District, Selangor.

Autor:	Farhani S; Klinik Kesihatan Tanjung Karang, Jalan Sungai Kajang, Tanjung Karang, Selangor, Malaysia., Sulizah S; Klinik Kesihatan Kuala Selangor, Jalan Klinik, Kuala Selangor, Selangor Malaysia., Siti Khalimah R; Klinik Kesihatan Sungai Tengi Kanan, Jalan Kiai Moid, Tanjung Karang, Selangor, Malaysia., Jasrinjeet Kaur K; Klinik Kesihatan Tanjung Karang, Jalan Sungai Kajang, Tanjung Karang, Selangor, Malaysia., Nur Hidayah Z; Klinik Kesihatan Kuala Selangor, Jalan Klinik, Kuala Selangor, Selangor Malaysia., Nur Athirah R; Klinik Kesihatan Tanjung Karang, Jalan Sungai Kajang, Tanjung Karang, Selangor, Malaysia. trahrosli@yahoo.com., Fateen Nadhira I; Klinik Kesihatan Tanjung Karang, Jalan Sungai Kajang, Tanjung Karang, Selangor, Malaysia., Noor Rafizah AA; Pejabat Kesihatan Daerah Kuala Selangor, Jalan Semarak, Kuala Selangor, Selangor, Malaysia.
Jazyk:	angličtina
Zdroj:	The Medical journal of Malaysia [Med J Malaysia] 2024 Jan; Vol. 79 (1), pp. 68-73.
Abstrakt:	Introduction: Studies showed that vildagliptin can lower HbA1c levels by 0.8%-1%. However, there is limited data looking at vildagliptin use among suburban populations. The efficacy of vildagliptin use may differ among different populations, especially those with low socio-economic status. Thus, this study aimed to assess the HbA1c reduction after vildagliptin initiation, treatment patterns and the reason for its initiation among patients with type 2 diabetes mellitus attending outpatient clinics in Kuala Selangor District, Selangor. Materials and Methods: This is a cross-sectional, retrospective study design. All patients who received vildagliptin in the Pharmacy Integrated Health System (PHIS) registry database from 2016 to 2021 were included as study samples. The exclusion criteria were being less than 18 years old and having type 1 diabetes mellitus. Patients' medical records were retrieved after sampling, and data were collected. One medical record was missing, thus SPSS analysis were performed on 144 vildagliptin users. Results: In total, 84 females (58.3%) and 60 males (41.7%) with a mean age of 62.1 (±10.1) years were analysed in this study. Mean HbA1c pre-therapy was 8.5 ± 2.1%; while posttherapy 6 months demonstrated a mean HbA1c of 7.9 ± 1.8%. Use of vildagliptin alone or as an adjunct was associated with a mean reduction of 0.6% in HbA1c (p = 0.01). Factors influencing this HbA1c reduction were advancing age, specifically individuals aged 62 years and older (p = 0.02), patients who are already receiving insulin therapy (p=0.00) and those who express a willingness to commence insulin treatment during the counselling session prior to initiating the treatment plan (p = 0.00). Reasons for vildagliptin initiation documented by prescribers were non-insulin acceptance (n = 59, 40.97%), frequent hypoglycaemia (n = 6, 4.1%) and non-compliance with medications (n = 23, 15.9%). There was no association between demographic, medical background and reason for starting vildagliptin variables and HbA1c reduction (p < 0.001). Conclusion: This study showed that initiating vildagliptin alone or as an adjunct therapy significantly reduced HbA1c and is beneficial for uncontrolled diabetes patients. While advancing age, concurrent administration of insulin and the patients' willingness to accept insulin treatment prior to the commencement of therapy were the factors that influenced HbA1c reduction among patients receiving vildagliptin therapy, we recommend primary care providers prioritise all of the significant variables discovered before initiating vildagliptin for their patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu